Considered a bioregulator, Cardiogen is a short peptide distinguished by several features focused on fibroblasts. Fibroblasts are cells that are thought to be important for tissue healing and scar ...
February 16, 2012 (Rockville, Maryland)— The US Food and Drug Administration (FDA) is notifying physicians that CardioGen-82 (Bracco Diagnostics), a generator used at clinical sites to produce the ...
Silver Spring, MD - In an update on its inquiry into problems with the CardioGen-82 (Bracco Diagnostics), used in cardiac positron-emission-tomography (PET) scans, the US FDA says that "improper usage ...
BGI Genomics, together with the National Center for Cardiovascular Diseases, Fuwai Hospital, and the State Key Laboratory of Cardiovascular Diseases, is pleased to ...
The exploration of bioactive peptides has opened avenues for understanding complex biochemical processes and their potential implications across various scientific disciplines. Among these, Cardiogen ...
Monogenic cardiovascular disease is a genetic disease in which cardiovascular damage is the only or main phenotype. The total current number of patients worldwide exceeds 10 million. In 2019, the ...
Please provide your email address to receive an email when new articles are posted on . The FDA is updating health care professionals and the public about preliminary findings from ongoing ...
BGI Genomics-led team builds CardioGen to help clinicians diagnose monogenic cardiovascular diseases
Monogenic cardiovascular disease is a genetic disease in which cardiovascular damage is the only or main phenotype. The total current number of patients worldwide exceeds 10 million. In 2019, the ...
SAN FRANCISCO--(BUSINESS WIRE)--Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare ...
Audentes Therapeutics said today it has acquired adeno-associated virus (AAV) gene therapy developer Cardiogen Sciences for an undisclosed price. Audentes said it plans to “rapidly” advance into ...
Audentes Therapeutics said today it has acquired adeno-associated virus (AAV) gene therapy developer Cardiogen Sciences for an undisclosed price. Audentes said it plans to “rapidly” advance into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results